Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension

Hypertension

Volumn 51, Issue 4, 2008, Pages 862-866

  Van Den Born, Bert Jan H ^a   Van Der Hoeven, Niels V ^a   Groot, Evelyn ^b   Lenting, Peter J ^b   Meijers, Joost C M ^a   Levi, Marcel ^a   Van Montfrans, Gert A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Coagulation; Endothelium; Hypertensive crisis; Kidney failure; Thrombotic microangiopathy

Indexed keywords

ANTIHYPERTENSIVE AGENT; CREATININE; HEMOGLOBIN; LACTATE DEHYDROGENASE; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENDOTHELIUM; ENZYME ACTIVITY; ENZYME DEFICIENCY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MALIGNANT HYPERTENSION; PREDICTOR VARIABLE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STIMULATION; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; ACUTE DISEASE; BLOOD; CASE CONTROL STUDY; HOSPITALIZATION; KIDNEY FAILURE; METABOLISM; MICROCIRCULATION; PROSPECTIVE STUDY; RENOVASCULAR HYPERTENSION; THROMBOSIS; VASCULAR ENDOTHELIUM;

ACUTE DISEASE; ADAM PROTEINS; ADULT; CASE-CONTROL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HEMOGLOBINS; HUMANS; HYPERTENSION, MALIGNANT; HYPERTENSION, RENAL; KIDNEY FAILURE; MALE; MICROCIRCULATION; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 42049119459     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.103127     Document Type: Article

References (19)

1. van den Born BJ, Honnebier UP, Koopmans RP, van Montfrans GA. Microangiopathic hemolysis and renal failure in malignant hypertension. Hypertension. 2005;45:246-251.
2. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339:1578-1584.
3. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585-1594.
4. Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest. 1986;78:1456-1461.
5. Reiter RA, Knobl P, Varadi K, Turecek PL. Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin. Blood. 2003;101:946-948.
6. Ono T, Mimuro J, Madoiwa S, Soejima K, Kashiwakura Y, Ishiwata A, Takano K, Ohmori T, Sakata Y. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood. 2006;107:528-534.
7. Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, Schade AJ, McIntire LV, Fujikawa K, Lopez JA. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002;100:4033-4039.
8. Hulstein JJ, de Groot PG, Silence K, Veyradier A, Fijnheer R, Lenting PJ. A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. Blood. 2005;106:3035-3042.
9. Studt JD, Hovinga JA, Antoine G, Hermann M, Rieger M, Scheiflinger F, Lammle B. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood. 2005;105:542-544.
10. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005;129:93-100.
11. Raines G, Aumann H, Sykes S, Street A. Multimeric analysis of von Willebrand factor by molecular sieving electrophoresis in sodium dodecyl sulphate agarose gel. Thromb Res. 1990;60:201-212.
12. Banno F, Kokame K, Okuda T, Honda S, Miyata S, Kato H, Tomiyama Y, Miyata T. Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood. 2006;107:3161-3166.
13. Vesely SK, George JN, Lammle B, Studt JD, Alberio L, El Harake MA, Raskob GE. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102:60-68.
14. Cserti CM, Landaw S, Uhl L. Do infections provoke exacerbations and relapses of thrombotic thrombocytopenic purpura? J Clin Apher. 2007;22:21-25.
15. Reiter RA, Varadi K, Turecek PL, Jilma B, Knobl P. Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation. Thromb Haemost. 2005;93:554-558.
16. Ruggeri ZM. von Willebrand factor. J Clin Invest. 1997;99:559-564.
17. Nishio K, Anderson PJ, Zheng XL, Sadler JE. Binding of platelet glycoprotein Ibalpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13. Proc Natl Acad Sci U S A. 2004;101:10578-10583.
18. Donadelli R, Orje JN, Capoferri C, Remuzzi G, Ruggeri ZM. Size regulation of von Willebrand factor-mediated platelet thrombi by ADAMTS13 in flowing blood. Blood. 2006;107:1943-1950.
19. Mannucci PM, Capoferri C, Canciani MT. Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease. Br J Haematol. 2004;126:213-218.